Exelixis | EXEL - Trade Creditors


Exelixis reported $29.62M in Trade Creditors for its fiscal quarter ending in December of 2025.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 21.75M 1.65M Sep/2025
Agios Pharmaceuticals USD 18.36M 1.2M Dec/2025
Akebia Therapeutics USD 10.09M 1.47M Sep/2025
Amgen USD 20.89B 1.25B Dec/2025
AstraZeneca USD 25.28B 252M Dec/2025
Bayer EUR 6.38B 343M Sep/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Bristol-Myers Squibb USD 4.29B 1.14B Sep/2025
Cytokinetics USD 105.62M 83.53M Dec/2025
Eisai JPY 85.49B 4.76B Dec/2025
Eli Lilly USD 5.38B 1.12B Dec/2025
Esperion Therapeutics USD 77.51M 2.81M Sep/2025
Exelixis USD 29.62M 4.27M Dec/2025
Genmab DKK 6M 2M Sep/2025
Glaxosmithkline GBP 21.07B 7.42B Sep/2025
Incyte USD 1.63B 1.46B Dec/2025
Ionis Pharmaceuticals USD 14.33M 8.47M Sep/2025
MacroGenics USD 5.94M 1.28M Sep/2025
Merck USD 4.15B 102M Sep/2025
Moderna USD 317M 50M Dec/2025
Nektar Therapeutics USD 15.56M 1.28M Sep/2025
Neurocrine Biosciences USD 545.5M 425.6M Dec/2025
Novartis USD 4.56B 49M Sep/2025
Pfizer USD 5.02B 142M Sep/2025
Puma Biotechnology USD 6.39M 962K Sep/2025
Sanofi EUR 22.93B 2.89B Dec/2025
Takeda JPY 467.59B 28.61B Dec/2025
Ultragenyx Pharmaceutical USD 40.57M 6.33M Sep/2025
Xencor USD 9.08M 9.45M Sep/2025